The sharp Q1'26 revenue rebound and improving license margins suggest a potential turnaround, but the company remains unprofitable. Traders should monitor whether the $2.2M Q1 run rate sustains and whether break-even guidance for 2026 is credible given historical losses.
Price Chart
Executive Summary
BIO-key reported 2025 full-year revenue of $6.1M, down 12% YoY, with a wider net loss of $4.6M despite cost reductions. However, preliminary Q1'26 revenue surged 37% YoY to $2.2M, signaling a strong rebound. The company highlighted improved gross margins in license fees, a growing defense sector pipeline, and key partnerships with TD Synnex and foreign financial institutions.
Key Financial Metrics
Key Facts
- 2025 revenue was $6.1M, down 12% from $6.9M in 2024, primarily due to lower license fee revenue and transition in EMEA region
- Net loss increased to $4.6M in 2025 from $4.3M in 2024, but per-share loss improved to ($0.69) from ($2.09) due to higher share count
- Preliminary Q1'26 revenue is $2.2M, up 37% YoY and 80% QoQ, indicating strong near-term momentum
- Gross margin on license fees improved to 91.3% in 2025 from 88.6% in 2024 due to shift to BIO-key branded products in EMEA
- Cash position increased to $2.7M at year-end 2025 from $0.4M in 2024, and book value nearly doubled to $7.7M
- Secured $500k in new defense orders in Q1'26 and a $1M license renewal from a foreign retail bank
Financial Impact
2025 revenue decline of 12% and increased net loss, but Q1'26 revenue up 37% YoY; cash flow improved via financing and warrant exercises
Risk Factors
- 2025 financials are unaudited and subject to change
- Revenue remains highly volatile and concentrated in large contracts
- Continued net losses and reliance on financing activities to sustain operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | S-1 | $1.65 | awaiting T+60 | — | $2.85 (−72.73%) |
Oct 6, 2026 20d ago | DEFA14A | $1.76 | awaiting T+60 | — | $2.85 (+61.93%) |
Oct 6, 2026 20d ago | 8-K | $1.76 | awaiting T+60 | — | $2.85 (+61.93%) |
Oct 2, 2026 23d ago | 8-K | $1.93 | awaiting T+60 | — | $2.85 (−47.67%) |
Sep 29, 2026 27d ago | Press Release | $3.12 | awaiting T+60 | — | $2.85 (−8.65%) |
Aug 24, 2026 9w ago | DEFA14A | $2.97 | awaiting T+60 | — | $2.85 (+4.04%) |
Aug 14, 2026 10w ago | 8-K | $3.18 | awaiting T+60 | — | $2.85 (+10.38%) |
Aug 13, 2026 10w ago | Press Release | $3.18 | awaiting T+60 | — | $2.85 (−10.38%) |
Aug 10, 2026 11w ago | Press Release | $4.17 | awaiting T+60 | — | $2.85 (−31.65%) |
Jul 28, 2026 12w ago | Press Release | $4.25 $2.10 | ▼ −50.59% | ▼ −54.94% | $2.85 (−32.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers